Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2a + imatinib
- Development stage
- Unknown
- Lead developer
- pharma&
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
peginterferon alfa-2a + imatinib is a combination therapy evaluated for the treatment of chronic myeloid leukemia (CML). It consists of peginterferon alfa-2a, a pegylated recombinant interferon, and imatinib mesylate, a small-molecule tyrosine kinase inhibitor. Peginterferon alfa-2a exerts its effects by binding to the interferon-alpha receptor (IFNAR), inducing antiproliferative, antiviral, and immunomodulatory activities. Imatinib specifically inhibits the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome (Ph+) that drives the uncontrolled proliferation of myeloid cells in CML. This combination was investigated by Hospices Civils de Lyon, particularly in the SPIRIT trial and Phase II studies, to overcome resistance to imatinib monotherapy and enhance molecular response rates in patients with chronic-phase CML.
- Other names
- peginterferon alfa-2a and imatinib mesylate combinationPeg-Interferon + ImatinibPegasys + GleevecPegasys + Glivec
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFR (PDGFR family)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on peginterferon alfa-2a + imatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2a + imatinib.